Equities researchers at Wall Street Zen upgraded Structure Therapeutics (NASDAQ:GPCR) from a “sell” rating to a “hold” rating, as detailed in a report released on Saturday. This change reflects the evolving sentiment around the company amid a backdrop of varying opinions from other analysts regarding its stock performance.
Analyst Ratings and Price Targets
On November 28, HC Wainwright reaffirmed a “buy” rating for Structure Therapeutics, setting a price target at $60.00. In a separate report, Morgan Stanley raised its price target from $120.00 to $125.00, maintaining an “overweight” rating. Meanwhile, Stifel Nicolaus increased their price objective from $50.00 to $90.00, also issuing a “buy” rating on December 8.
Contrastingly, Zacks Research downgraded the stock from a “hold” to a “strong sell” rating on October 17. In a more positive note, Lifesci Capital upgraded Structure Therapeutics to a “strong buy” on September 8. Currently, one analyst has rated the stock as a strong buy, eleven have given it a buy rating, and two have issued a sell rating. According to data from MarketBeat, Structure Therapeutics has an average rating of “moderate buy” with an average target price of $95.78.
Recent Earnings and Investor Activity
Structure Therapeutics announced its quarterly earnings results on November 6, reporting a loss of $0.37 earnings per share, which fell short of the consensus estimate of $0.36 by $0.01. Analysts project that the company will report earnings of -$0.82 per share for the current fiscal year.
Institutional investors have shown varying interest in Structure Therapeutics recently. The State of Wyoming acquired a new stake in the company during the second quarter, valued at approximately $28,000. EverSource Wealth Advisors LLC significantly increased its holdings by 530.0% in the third quarter, now owning 1,071 shares valued at $30,000.
Additionally, the National Bank of Canada FI raised its position by an impressive 1,448.2%, holding 2,957 shares worth $51,000. Assetmark Inc. and PNC Financial Services Group Inc. also increased their stakes, now owning 2,877 shares valued at $60,000 and 4,415 shares worth $92,000, respectively. Overall, approximately 91.78% of the stock is owned by hedge funds and institutional investors.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapeutics to address chronic diseases with significant unmet medical needs. Its lead product candidate, GSBR-1290, is an oral small molecule agonist targeting the glucagon-like peptide-1 receptor, which is crucial in treating type-2 diabetes and obesity.
As the company navigates its market presence, the mixed ratings and substantial involvement from institutional investors signal ongoing interest in its future potential.
